Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 5

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Ovarian cancer recurrent

Recruiting

Evaluation of Raludotatug Deruxtecan With Carboplatin, Paclitaxel, or Bevacizumab in Relapsed High-grade Serous Ovarian, Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Hormone receptor positive breast cancer

Recruiting

A Study of Camizestrant and Ribociclib for Patients with Hormone Receptor-Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Prostate cancer metastatic

Recruiting

A study testing the safety and effectiveness of AZD0516 alone and with other cancer drugs in adults with metastatic prostate cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD0516
  • Sponsor:AstraZeneca AB

Adrenogenital syndrome

Recruiting

A Study Testing Atumelnant Compared to Placebo in Adults with Classic Congenital Adrenal Hyperplasia to Reduce Steroid Dose While Controlling Hormones

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Adrenogenital syndrome

Recruiting

A Study of Atumelnant for Children with Congenital Adrenal Hyperplasia

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

HER2 positive endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Neoplasm malignant+1

Recruiting

Study of ECI830, ribociclib, and fulvestrant in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Novartis Pharma AG

Bacterial vaginosis

Recruiting

A study comparing furazidin and clindamycin for women with bacterial vaginosis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Clindamycin Phosphate
  • Sponsor:Adamed Pharma S.A.

Hormone receptor negative HER2 positive breast cancer

Recruiting

Exercise Program Study for Early Breast Cancer Patients Taking Aromatase Inhibitors With or Without CDK4/6 Inhibitors to Improve Quality of Life

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Breast cancer+1

Recruiting

Study of inavolisib and fulvestrant for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:F. Hoffmann-La Roche AG

Ovarian cancer

Recruiting

Study of Tumor-Infiltrating Lymphocyte Cell Therapy and Aldesleukin for Patients with Advanced Stage Ovarian Cancer as Initial Treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:TIL cells
  • Sponsor:Leiden University Medical Center

Endometrial cancer+3

Recruiting

Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.